PSYCHEDELIC THERAPY
Ketamine-Assisted Psychotherapy (KAP)
I offer a therapeutic modality called Ketamine-Assisted Psychotherapy (KAP) in partnership with an organization called Journey Clinical.
Ketamine-Assisted Psychotherapy (KAP) is a holistic modality in which ketamine is used as a complement to psychotherapy to help eligible patients experience more frequent breakthroughs and sustained improvement in symptoms. I take on the psychotherapy portion of the experience, while Journey Clinical’s medical team supports you on all medical aspects. This includes determining eligibility, developing a custom treatment plan, prescribing the medicine and monitoring outcomes. Here’s a link to more information about KAP to see if it may be a good fit for you. https://journey.click/education
Frequently Asked Questions
-
KAP is a legal modality that pairs ketamine treatment with dedicated psychotherapy sessions for more deeper therapy, more frequent breakthroughs and better clinical outcomes. To learn more about KAP, visit https://journey.click/education
-
Ketamine is a legal, safe and effective medicine used to treat a variety of mental health conditions, including depression, anxiety and PTSD. Ketamine has rapidly-acting antidepressant and mood-enhancing effects, which can begin to take effect within 1-2 hrs. after treatment and last for up to 2 weeks. It works by blocking the brain’s NMDA receptors as well as by stimulating AMPA receptors, which are thought to help form new synaptic connections and boost neural circuits that regulate stress and mood. Ketamine has also been shown to enhance overall neuroplasticity for lasting symptom improvement.
Ketamine can be administered in a variety of ways, including IV infusion, intramuscular injection, via nasal spray and using sublingual lozenges. In my work with Journey Clinical we only use the sublingual lozenge form.
-
The effects of ketamine, which most patients find pleasant, last for approximately 45 minutes. These effects can make you feel “far from” your body, and facilitate shifts in perception that can often feel expansive in nature. Your motor and verbal abilities will be reduced, so you’ll be lying down in a comfortable position during the experience. Once these effects subsided, we’ll spend the remainder of our appointment giving you space to process and discuss your experience. While it may feel hard to articulate what happened during the experience, patients feel like the insights gained are none-the-less clear. Studies have shown that the benefits to mood and neurological growth can last up to two weeks after the Ketamine experience.
-
People often explore KAP after doing a lot of work and still feeling stuck. Research is strongest for treatment-resistant depression. Evidence for PTSD and refractory anxiety is promising and growing, while OCD, substance-use disorders, and other conditions have smaller, more condition-specific research bases. That distinction matters: fit depends on what you are trying to treat and how the therapy is structured.
For depression research, response usually means symptoms decreased by at least 50%. Remission means symptoms fell below the study’s clinical threshold. A large real-world meta-analysis found average rates of 45% response and 30% remission. In a prospective study of four sessions of sublingual ketamine-assisted therapy, 62.8% met response criteria and 32.6% reached remission. A small 2026 KAP case series involving 12 people reported 67% response and 58% remission.
Across those studies, published response rates range from about 45–67%, with remission rates around 30–58%. That gives us a meaningful benchmark, not a prediction of any one person’s outcome.
Those numbers matter, but they are not the whole person. I’m interested in your history, what has and hasn’t helped, and what kind of change you are seeking. We explore fit together, with Journey Clinical’s medical team handling the medical evaluation.
Depression outcomes: Alnefeesi et al. (2022), real-world systematic review and meta-analysis; Hull et al. (2022), prospective sublingual ketamine-assisted therapy study; Cohen et al. (2026), ketamine combined with psychotherapy case series.
Other conditions: Whittaker et al. (2021), anxiety-spectrum systematic review and meta-analysis; Almeida et al. (2024), PTSD systematic review and meta-analysis; Glue et al. (2024), randomized OCD trial.
-
KAP experiential dosing sessions can be generally planned every two weeks, although a customized treatment plan and schedule may involve weekly or monthly sessions. Much of the change process happens after the experiential sessions, so allowing space for integration is a crucial part of KAP.
-
Journey Clinical is a platform for licensed psychotherapists to incorporate science-based psychedelic therapies in their practice safely and effectively, starting with Ketamine-Assisted Psychotherapy (KAP). Journey Clinical’s in-house medical team takes on patient eligibility, prescriptions and outcome monitoring, while I take on the therapy. Their collaborative care model is designed to deliver personalized treatment plans to meet your individual needs and improve long-term outcomes.
Our Story